Bicycle Cash And Short Term Investments vs Capital Surpluse Analysis

BCYC Stock

USD 23.03 0.45 1.92%

Bicycle Therapeutics financial indicator trend analysis is way more than just evaluating Bicycle Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bicycle Therapeutics is a good investment. Please check the relationship between Bicycle Therapeutics Cash And Short Term Investments and its Capital Surpluse accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.

Cash And Short Term Investments vs Capital Surpluse

Cash And Short Term Investments vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bicycle Therapeutics Cash And Short Term Investments account and Capital Surpluse. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Bicycle Therapeutics' Cash And Short Term Investments and Capital Surpluse is 0.85. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Bicycle Therapeutics, assuming nothing else is changed. The correlation between historical values of Bicycle Therapeutics' Cash And Short Term Investments and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Bicycle Therapeutics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Cash And Short Term Investments i.e., Bicycle Therapeutics' Cash And Short Term Investments and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.85

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Bicycle Therapeutics balance sheet. This account contains Bicycle Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Bicycle Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Capital Surpluse

Most indicators from Bicycle Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bicycle Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.At present, Bicycle Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 267.8 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.89.

Bicycle Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Net Receivables	Capital Surpluse	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Non Current Liabilities Total	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.95	0.98	0.97	0.96	-0.97	0.86	1.0	0.93	1.0	0.84	0.86	0.99	0.79	1.0	0.97	0.96	0.86	0.87	-0.99	0.85	0.77	0.9	0.07	0.98	0.95
Other Current Liab	0.95		0.98	0.9	0.9	-0.98	0.89	0.94	0.99	0.94	0.91	0.86	0.96	0.78	0.94	0.95	0.97	0.87	0.82	-0.91	0.87	0.85	0.89	0.02	0.92	0.96
Total Current Liabilities	0.98	0.98		0.93	0.92	-0.99	0.92	0.97	0.98	0.97	0.86	0.84	0.99	0.77	0.97	0.96	0.99	0.86	0.86	-0.96	0.86	0.8	0.91	0.09	0.95	0.98
Total Stockholder Equity	0.97	0.9	0.93		0.99	-0.92	0.81	0.97	0.86	0.97	0.77	0.88	0.97	0.63	0.97	0.96	0.93	0.85	0.89	-0.98	0.84	0.72	0.88	-0.04	0.99	0.93
Net Tangible Assets	0.96	0.9	0.92	0.99		-0.9	0.75	0.96	0.86	0.96	0.81	0.92	0.96	0.67	0.96	0.97	0.91	0.87	0.89	-0.96	0.86	0.76	0.88	-0.12	1.0	0.92
Retained Earnings	-0.97	-0.98	-0.99	-0.92	-0.9		-0.94	-0.96	-0.98	-0.96	-0.86	-0.84	-0.98	-0.76	-0.96	-0.96	-0.98	-0.85	-0.84	0.95	-0.85	-0.78	-0.9	-0.09	-0.94	-0.96
Accounts Payable	0.86	0.89	0.92	0.81	0.75	-0.94		0.86	0.91	0.86	0.68	0.65	0.89	0.65	0.86	0.83	0.93	0.71	0.69	-0.87	0.71	0.64	0.77	0.26	0.8	0.9
Cash	1.0	0.94	0.97	0.97	0.96	-0.96	0.86		0.92	1.0	0.82	0.85	0.99	0.78	1.0	0.96	0.95	0.84	0.87	-0.99	0.83	0.74	0.89	0.08	0.98	0.95
Other Assets	0.93	0.99	0.98	0.86	0.86	-0.98	0.91	0.92		0.92	0.9	0.81	0.95	0.81	0.93	0.92	0.97	0.85	0.79	-0.89	0.86	0.85	0.87	0.09	0.89	0.96
Cash And Short Term Investments	1.0	0.94	0.97	0.97	0.96	-0.96	0.86	1.0	0.92		0.82	0.85	0.99	0.78	1.0	0.96	0.95	0.84	0.87	-0.99	0.83	0.74	0.89	0.08	0.98	0.95
Net Receivables	0.84	0.91	0.86	0.77	0.81	-0.86	0.68	0.82	0.9	0.82		0.83	0.84	0.85	0.83	0.86	0.83	0.87	0.83	-0.78	0.88	0.87	0.9	-0.02	0.82	0.82
Capital Surpluse	0.86	0.86	0.84	0.88	0.92	-0.84	0.65	0.85	0.81	0.85	0.83		0.89	0.59	0.86	0.95	0.8	0.75	0.74	-0.81	0.74	0.67	0.75	-0.42	0.91	0.79
Other Stockholder Equity	0.99	0.96	0.99	0.97	0.96	-0.98	0.89	0.99	0.95	0.99	0.84	0.89		0.73	0.99	0.99	0.97	0.86	0.87	-0.98	0.85	0.76	0.89	0.01	0.98	0.96
Total Liab	0.79	0.78	0.77	0.63	0.67	-0.76	0.65	0.78	0.81	0.78	0.85	0.59	0.73		0.79	0.7	0.74	0.74	0.72	-0.74	0.75	0.74	0.79	0.3	0.7	0.73
Total Current Assets	1.0	0.94	0.97	0.97	0.96	-0.96	0.86	1.0	0.93	1.0	0.83	0.86	0.99	0.79		0.97	0.95	0.84	0.87	-0.99	0.84	0.75	0.89	0.07	0.98	0.95
Common Stock	0.97	0.95	0.96	0.96	0.97	-0.96	0.83	0.96	0.92	0.96	0.86	0.95	0.99	0.7	0.97		0.93	0.83	0.84	-0.94	0.82	0.74	0.86	-0.14	0.98	0.92
Property Plant Equipment	0.96	0.97	0.99	0.93	0.91	-0.98	0.93	0.95	0.97	0.95	0.83	0.8	0.97	0.74	0.95	0.93		0.9	0.85	-0.95	0.9	0.84	0.9	0.12	0.93	1.0
Property Plant And Equipment Net	0.86	0.87	0.86	0.85	0.87	-0.85	0.71	0.84	0.85	0.84	0.87	0.75	0.86	0.74	0.84	0.83	0.9		0.93	-0.85	1.0	0.95	0.94	0.08	0.86	0.92
Current Deferred Revenue	0.87	0.82	0.86	0.89	0.89	-0.84	0.69	0.87	0.79	0.87	0.83	0.74	0.87	0.72	0.87	0.84	0.85	0.93		-0.89	0.91	0.79	0.98	0.15	0.89	0.87
Net Debt	-0.99	-0.91	-0.96	-0.98	-0.96	0.95	-0.87	-0.99	-0.89	-0.99	-0.78	-0.81	-0.98	-0.74	-0.99	-0.94	-0.95	-0.85	-0.89		-0.83	-0.72	-0.9	-0.14	-0.97	-0.94
Non Current Assets Total	0.85	0.87	0.86	0.84	0.86	-0.85	0.71	0.83	0.86	0.83	0.88	0.74	0.85	0.75	0.84	0.82	0.9	1.0	0.91	-0.83		0.96	0.94	0.09	0.85	0.92
Non Currrent Assets Other	0.77	0.85	0.8	0.72	0.76	-0.78	0.64	0.74	0.85	0.74	0.87	0.67	0.76	0.74	0.75	0.74	0.84	0.95	0.79	-0.72	0.96		0.85	0.07	0.75	0.87
Common Stock Shares Outstanding	0.9	0.89	0.91	0.88	0.88	-0.9	0.77	0.89	0.87	0.89	0.9	0.75	0.89	0.79	0.89	0.86	0.9	0.94	0.98	-0.9	0.94	0.85		0.2	0.89	0.91
Non Current Liabilities Total	0.07	0.02	0.09	-0.04	-0.12	-0.09	0.26	0.08	0.09	0.08	-0.02	-0.42	0.01	0.3	0.07	-0.14	0.12	0.08	0.15	-0.14	0.09	0.07	0.2		-0.07	0.12
Net Invested Capital	0.98	0.92	0.95	0.99	1.0	-0.94	0.8	0.98	0.89	0.98	0.82	0.91	0.98	0.7	0.98	0.98	0.93	0.86	0.89	-0.97	0.85	0.75	0.89	-0.07		0.93
Property Plant And Equipment Gross	0.95	0.96	0.98	0.93	0.92	-0.96	0.9	0.95	0.96	0.95	0.82	0.79	0.96	0.73	0.95	0.92	1.0	0.92	0.87	-0.94	0.92	0.87	0.91	0.12	0.93

Click cells to compare fundamentals

Bicycle Therapeutics Account Relationship Matchups

Bicycle Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	110.2M	161.2M	479.8M	410.6M	595.3M	625.1M
Other Current Liab	5.5M	10.8M	11.9M	23.3M	26.6M	28.0M
Total Current Liabilities	8.8M	23.1M	36.2M	53.3M	69.5M	73.0M
Total Stockholder Equity	93.2M	95.5M	346.3M	270.8M	370.9M	389.5M
Other Liab	6.9M	27.6M	55.3M	45.3M	52.1M	26.8M
Net Tangible Assets	93.2M	95.5M	346.3M	270.8M	311.4M	327.0M
Retained Earnings	(100.6M)	(151.6M)	(218.4M)	(331.1M)	(511.8M)	(486.2M)
Accounts Payable	1.9M	1.4M	2.7M	6.5M	13.1M	13.7M
Cash	92.1M	136.0M	438.7M	339.2M	526.4M	552.7M
Other Assets	1.7M	3.1M	3.4M	8.5M	9.7M	10.2M
Cash And Short Term Investments	92.1M	136.0M	438.7M	339.2M	526.4M	552.7M
Net Receivables	7.1M	14.6M	11.9M	21.2M	24.0M	13.0M
Common Stock Total Equity	5K	10K	227K	266K	305.9K	321.2K
Other Current Assets	4.9M	5.1M	8.0M	9.0M	11.4M	12.0M
Other Stockholder Equity	195.1M	249.9M	567.6M	601.1M	883.4M	927.6M
Total Liab	17.0M	65.7M	133.5M	139.8M	224.4M	117.8M
Total Current Assets	104.1M	155.7M	458.6M	369.4M	561.9M	590.0M
Accumulated Other Comprehensive Income	(1.5M)	(3.2M)	(3.4M)	387K	(1.3M)	(1.4M)
Short Term Debt	640K	844K	2.4M	3.1M	4.9M	5.1M
Common Stock	227K	266K	384K	387K	550K	577.5K
Property Plant Equipment	4.3M	3.6M	17.8M	32.8M	37.7M	39.6M
Property Plant And Equipment Net	4.3M	3.6M	17.8M	32.8M	27.7M	14.0M
Current Deferred Revenue	728K	10.1M	19.3M	20.4M	25.0M	12.5M
Net Debt	(90.2M)	(120.2M)	(394.3M)	(294.8M)	(481.5M)	(457.4M)
Non Current Assets Total	6.0M	5.4M	21.2M	41.2M	33.5M	18.0M
Non Currrent Assets Other	1.7M	1.8M	3.4M	8.5M	5.2M	3.9M
Common Stock Shares Outstanding	11.0M	19.1M	25.1M	29.7M	35.6M	23.1M
Liabilities And Stockholders Equity	110.2M	161.2M	479.8M	410.6M	595.3M	300.6M
Non Current Liabilities Total	8.2M	42.6M	97.3M	86.5M	154.9M	101.1M
Net Invested Capital	93.2M	110.0M	376.1M	301.1M	401.6M	421.7M
Property Plant And Equipment Gross	4.3M	3.6M	22.6M	40.6M	41.1M	43.1M
Non Current Liabilities Other	2.0M	2.6M	3.3M	3.8M	4.6M	2.8M
Net Working Capital	95.3M	132.6M	422.3M	316.0M	492.3M	249.6M
Capital Stock	227K	266K	384K	387K	550K	334.4K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
GM	General Motors
CRM	Salesforce

When determining whether Bicycle Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bicycle Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bicycle Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bicycle Therapeutics Stock:

How To Invest In Bicycle

Details

Is Bicycle Stock a good investment?

Details

What is Bicycle Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Bicycle Stock analysis

When running Bicycle Therapeutics' price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is Bicycle Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.40)

Revenue Per Share

1.074

Quarterly Revenue Growth

2.989

Return On Assets

(0.23)

Return On Equity

(0.56)

The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bicycle Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bicycle Cash And Short Term Investments vs Capital Surpluse Analysis

Cash And Short Term Investments vs Capital Surpluse

Cash And Short Term Investments vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Capital Surpluse

Bicycle Therapeutics fundamental ratios Correlations

Bicycle Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bicycle Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Bicycle Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Net Tangible Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Net Debt	- 0.99	Total Current Assets
Net Debt	- 0.99	Cash And Short Term Investments
Net Debt	- 0.99	Cash
Retained Earnings	- 0.99	Total Current Liabilities
Net Debt	- 0.99	Total Assets
Net Debt	- 0.98	Other Stockholder Equity